Ben McPoland considers a pair of investments that are performing awfully in his ISA portfolio so far this year. What's gone ...

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) sent a letter to the U.S. Food & Drug Administration (FDA), along with more than 20 leading organizations and providers across ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Last month, the U.S. Food and Drug Administration (the “FDA”) announced in a Declaratory Order the resolution of the shortage of semaglutide ...

The War and Treaty singer Michael Trotter Jr. tells PEOPLE ahead of the 'Opry 100: A Live Celebration' in Nashville on March ...

Hypera plans to introduce a generic version of semaglutide in Brazil following patent expiration in 2026. The company is optimistic about market growth despite potential price impacts. Analysts ...

Copycat versions of Eli Lilly’s diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They’re ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...